Abstracts tagged "patient outcomes"

Abstract Number: 050 • 2023 Pediatric Rheumatology Symposium
Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort
Sara Patrizi¹, Megha Tandel², Derek Boothroyd² and Joyce Hsu¹, ¹Stanford Medicine, Children's Health, Palo Alto, CA, ²Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: In 2019, new classification criteria for SLE were developed by the EULAR/ACR. Prior research in adult lupus cohorts found a positive correlation between high…
Abstract Number: 084 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease Shock Syndrome: A Single Center Cohort
Monica Bray¹, Jennifer Rammel ², Andrea Ramirez ³, Kristen Sexson ⁴, Fong Lam ⁵, Eyal Muscal ¹ and Marietta De Guzman ³, ¹Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ²Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, ⁵Section of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a well described vasculitis of childhood that is the leading cause of acquired heart disease in developed countries. Kawasaki disease…
Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
Ugo Awa¹, Monica Bray ² and Marietta De Guzman ³, ¹Baylor College of Medicine, Houston, ²Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
Abstract Number: 132 • 2020 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit
Jennifer Rammel¹, Kristen Staggers ², Satid Thammasitboon ², Jorge Coss Bu ², Amanda Brown ³ and Eyal Muscal ⁴, ¹Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ²Baylor College of Medicine, Houston, Texas, ³Baylor College of Medicine, Houston, ⁴Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston
Background/Purpose: Pediatric rheumatology has been an evolving subspecialty over the last few decades with a continued increase in the both the number and severity of…
Abstract Number: 834 • 2019 ACR/ARP Annual Meeting
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Shanthini Kasturi¹, John Wong ¹, Lisa Mandl ², Timothy McAlindon ³ and Amy LeClair ¹, ¹Tufts Medical Center, Boston, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ³Tufts Medical Center, Boston, MA
Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…
Abstract Number: 876 • 2019 ACR/ARP Annual Meeting
“When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study
Erika Mosor¹, Paul Studenic ¹, Alessia Alunno ², Ivan Padjen ³, Wendy Olsder ⁴, Sofia Ramiro ⁵, Ilaria Bini ⁶, Nele Caeyers ⁷, Laure Gossec ⁸, Marios Kouloumas ⁹, Elena Nikiphorou ¹⁰, Simon Stones ¹¹, Tanita Wilhelmer ¹² and Tanja Stamm ¹, ¹Medical University of Vienna, Vienna, Austria, ²Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ³UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, ⁴Patient Research Partner, Amsterdam, Netherlands, ⁵Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ⁶ANMAR Young Patient Advocate, Avellino, Italy, ⁷Patient Research Partner, Brussels, Belgium, ⁸Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁹Cyprus League Against Rheumatism, Nicosia, Cyprus, ¹⁰King's College London, London, United Kingdom, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Österreichische Rheumaliga, Bregenz, Austria
Background/Purpose: Although patient-reported outcome measures (PROMs) are extensively used in clinical practice and research, it is unclear whether the most commonly used instruments adequately cover…
Abstract Number: 1153 • 2019 ACR/ARP Annual Meeting
Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population
Alice Fike¹, Yanira Ruiz-Perdomo ¹ and James Katz ¹, ¹NIAMS, BETHESDA, MD
Background/Purpose: The potential for reactivation of tuberculosis (TB) in patients treated with anti-TNF or other immunosuppressive agents has been well described. Interferon-gamma release assays (IGRA)…
Abstract Number: 1327 • 2019 ACR/ARP Annual Meeting
The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Yusuf Yazici¹, Sarah Kennedy ², Chris Swearingen ² and Jeyanesh Tambiah ², ¹Samumed, LLC, San Diego, CA, ²Samumed, LLC, San Diego
Background/Purpose: Lorecivivint (LOR, SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor which modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs)…
Abstract Number: 1361 • 2019 ACR/ARP Annual Meeting
Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Jatin Mistry ¹, Margaret Sibley ², Catherine Smith ³, Malama Sumbwanyambe ² and Patrick Kiely², ¹St George's University of London, London, United Kingdom, ²St George's University Hospitals NHS Trust, London, United Kingdom, ³St Georges University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ACR/EULAR guidelines recommend remission or low DAS28 as the treat to target goal for patients with rheumatoid arthritis (RA). Alternative patient reported outcomes include…
Abstract Number: 1839 • 2019 ACR/ARP Annual Meeting
Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
Hubert de BOYSSON¹, Eric LIOZON ², Olivier ESPITIA ³, Aurélie DAUMAS ⁴, Mathieu VAUTIER ⁵, Marc LAMBERT ⁶, Jean-Jacques PARIENTI ⁷, Alain MANRIQUE ⁷, David Saadoun ⁸, Kim Heang Ly ², Christian Agard ⁹ and Achille Aouba ¹⁰, ¹University Hospital of Caen, Caen, France, ²Limoges University Hospital, Limoges, France, ³Nantes University Hospital, Nantes, France, ⁴Marseille AP-HM, Marseille, France, ⁵Paris - Pitié salpétrière, Paris, France, ⁶Lille University Hospital, Lille, France, ⁷Caen University Hospital, Caen, France, ⁸AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ⁹CHU Nantes, Nantes, France, ¹⁰CHU Caen, Caen, France
Background/Purpose: Large-vessel involvements (LVI) in giant-cell arteritis (GCA) include different clinical and imaging patterns that are often pooled together in the published cohorts under the…
Abstract Number: 2192 • 2019 ACR/ARP Annual Meeting
Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA
Dawn McGuire¹, Michael Bowes ², Alan Brett ², Neil Segal ³, Meghan Miller ⁴, David Rosen ⁴ and Yoshinari Kumagai ⁴, ¹OrthoTrophix, Orinda, CA, ²Imorphics, Manchester, England, United Kingdom, ³University of Kansas Medical Center, Kansas City, KS, ⁴OrthoTrophix, Oakland, CA
Background/Purpose: Based on data from the Osteoarthritis Initiative (OAI), MRI-based analyses of bone shape changes in the knee predict symptomatic and radiographic progression of knee…
Abstract Number: 2242 • 2019 ACR/ARP Annual Meeting
Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis
Sarah Ahmed¹, Srita Chakka ², Rebecca Krain ³, Rui Feng ⁴ and Victoria Werth ⁵, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: The FDA uses near or total clearance in cutaneous disease in inflammatory skin conditions as an endpoint in clinical trials. However, patients may experience…
Abstract Number: 2256 • 2019 ACR/ARP Annual Meeting
Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
W. Benjamin Nowell¹, Elaine Karis ², Kelly Gavigan ¹, Laura Stradford ¹, Scott Stryker ³, Shilpa Venkatachalam ¹, Gregory Kricorian ³ and Jeffrey Curtis ⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations.…
Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Michelle Mulder¹, Alfons den Broeder ¹, Berbke van Ginneken ¹, Elien Mahler ¹, Frank van den Hoogen ¹, Johanna Vriezekolk ¹ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…
Abstract Number: 416 • 2019 ACR/ARP Annual Meeting
Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
Josep Verges¹, Marianna Vitaloni ¹, Rosa Sciortino ², Maritza Quintero ², Marco Bibas ¹, Jordi Monfort ³, Francisco de Abajo ⁴, Marco Matucci-Cerinic ⁵, Patrick du Souich ⁶, Ingrid Möller ⁷, Guy Eakin ⁸ and Angie Botto-van Bemden ⁸, ¹Osteoarthritis International Foundation, Barcelona, Spain, ²De los Andes University, Merida, Venezuela, ³Hospital del Mar, Barcelona, Spain, ⁴Universidad de Alcalá, Madrid, Spain, ⁵University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁶University of Montreal, Montreal, Canada, ⁷Poal Institute, Barcelona, Spain, ⁸Arthritis Foundation, Atlanta
Background/Purpose: Knee OA (KOA) associates with remarkable functional restrictions due to pain that seriously affect social and emotional well-being, reducing the quality of life (QoL).…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].